Quarterly report pursuant to Section 13 or 15(d)

Capital Deficiency

v3.22.2
Capital Deficiency
 3 Months Ended
Mar. 31, 2022
Capital Deficiency [Abstract]  
CAPITAL DEFICIENCY:

NOTE 9 – CAPITAL DEFICIENCY:

 

Share-based compensation

 

A summary of the Company’s share option activity under option plans is as follows:

 

      Number of
Options		     Weighted
Average
Exercise
Price		     Weighted
Average
Remaining
Contractual
Life		  
  Outstanding – January 1, 2021     879,251     $ 0.0874       6.25  
  Granted     43,261     $ 1.3616          
  Exercised     2,763     $ 0.1058          
  Expired and forfeited     29,256     $ 0.0874          
                           
  Outstanding – December 31, 2021     890,493     $ 0.1518       5.43  
                           
  Exercisable – December 31, 2021     801,562     $ 0.276       5.10  

 

      Number of
Options		       Weighted
Average
Exercise
Price		       Weighted
Average
Remaining
Contractual
Life		  
  Outstanding – January 1, 2022     890,493     $ 0.1518       5.43  
  Granted     -     $ -          
  Exercised     15,459     $ 0.0725          
  Expired and forfeited     1,862     $ 0.1058          
                           
  Outstanding – March 31, 2022     873,172     $ 0.1516       4.83  
                           
  Exercisable – March 31, 2022     799,692     $ 0.0917       5.13